Dogecoin Cash 3Q 2026: Revenue $164.42K, EPS $0 — 10-Q Summary

Dogecoin Cash reported a 14% revenue decline to $164.42K in Q3 2026, citing competitive pressure in cannabis telemedicine. EPS was $0. Operating expenses fell 26% to $200.31K. The company had $9.49K in cash and used $24.1K in operating activities. According to the company, unrealized investment gains and convertible loan value changes contributed to other income.

Original reporting
Published Nov 20, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dogecoin Cash 3Q 2026: Revenue $164.42K, EPS $0 — 10-Q Summary — source image
Decision brief

The 30-second read

$DOGPNeutralMed
01

Why it matters

Traders may reassess near-term liquidity risk and the sustainability of profitability, given revenue contraction alongside investment and fair-value gains.

02

Market read

A fresh quarterly disclosure with specific revenue, expense, and liquidity metrics, plus a loss-to-income shift supported by investment-related gains.

03

What to watch

Cash on hand is low ($9,485 at Sept. 30, 2026) and operating cash usage is negative ($24,103 for nine months), which may dominate valuation despite accounting profitability.

Relevance 6/10Novelty 6/10Timing: after-hours, based on a newly published 10-Q summary (Nov. 20, 2026)

Background

The piece summarizes Dogecoin Cash, Inc. (DOGP) 3Q 2026 results from an SEC 10-Q, attributing revenue weakness to competition in cannabis telemedicine.

Company-level read

Ticker impact

$DOGPNeutralMedium confidence
Context

Dogecoin Cash reported 3Q 2026 revenue down 14% and shifted earnings attributable to the company from a loss to income in its 10-Q summary.

Expected impact

Likely mixed reaction, with investors weighing weaker top-line against investment-driven earnings improvement and cash burn.

Evidence & confidence

The article provides specific revenue decline and expense reduction, plus sizable unrealized investment and fair-value gains that may be non-operating and volatile.

Market effects

Highlights competitive pressure in cannabis telemedicine demand, which can pressure revenue growth for similarly positioned healthcare-adjacent operators.

No clear regional market linkage beyond company-specific results.

Limited, as this is a single-company microcap-style quarterly disclosure with no stated cross-border catalyst.

Counterpoint

The earnings improvement may be largely driven by unrealized investment gains and convertible-loan fair value changes, which could reverse and leave core operations weaker.

Key entities

  • Dogecoin Cash, Inc.

    Issuer of the 10-Q summary; reported revenue decline, expense reduction, and investment/fair-value gains.

  • DogeCoin Cash, Inc. 10-Q (Nov. 20, 2026)

    Source of the reported financial highlights and liquidity figures.

Related articles

$HDMedAI 8/10

Home Depot Just Delivered Great News to Investors

Home Depot (HD) reported its strongest same-store sales growth since Q3 2022, with 2.2% global and U.S. growth. CFO Richard McPhail becomes CEO, while Ted Decker transitions to chairman. Revenue rose 4.9% to $43.4B, and adjusted EPS increased 3% to $3.86. The company updated its full-year guidance, expecting 4.5% sales growth and 2% EPS increase. Management highlighted strength in professional and high-ticket sales.

$HDMed

Mortgage Rates Have Jumped More Than 1 Point Since February. Home Depot and Lowe’s Shareholders Are Feeling the Pain.

Home Depot (HD) and Lowe's (LOW) reported declines in comparable transactions in Q3 2026, attributed to weak housing turnover due to rising mortgage rates. The 30-year fixed rate increased from 6.09% in February to 7.11%, impacting demand for home improvement services. Both companies saw same-store sales growth due to higher average ticket sizes, but overall performance lagged the market over the past three years.